特瑞普利单抗联合一线化疗在晚期非小细胞肺癌患者中的应用效果  

Application effect of toripalimab combined with first-line chemotherapy in patients with advanced non-small cell lung cancer

作　　者：李淑勤 冀俊琴 赵树强 LI Shuqin;JI Junqin;ZHAO Shuqiang(Department of Clinical Medicine,Fenyang College of Shanxi Medical University,Lvliang 032200,Shanxi,China;Department of Oncology,Shanxi Fenyang Hospital,Lvliang 032200,Shanxi,China;Department of Laboratory,Shanxi Fenyang Hospital,Lvliang 032200,Shanxi,China)

机构地区：[1]山西医科大学汾阳学院临床医学系,山西吕梁032200 [2]山西省汾阳医院肿瘤科,山西吕梁032200 [3]山西省汾阳医院检验科,山西吕梁032200

出　　处：《癌症进展》2025年第1期36-39,共4页Oncology Progress

基　　金：吕梁市重点研发项目(2024SHFZ31)。

摘　　要：目的探讨特瑞普利单抗联合一线化疗在晚期非小细胞肺癌(NSCLC)患者中的应用效果。方法依据治疗方案的不同将66例NSCLC患者分为常规组(n=30)和联合组(n=36),常规组患者行常规化疗,联合组患者行常规化疗+特瑞普利单抗治疗。比较两组患者的临床疗效、肿瘤标志物[细胞角质蛋白19片段抗原21-1(CYFRA21-1)、神经元特异性烯醇化酶(NSE)、癌胚抗原(CEA)]水平、细胞因子[γ干扰素(IFN-γ)、白细胞介素(IL)-2、肿瘤坏死因子-α(TNF-α)、IL-6、IL-10]水平和不良反应发生情况。结果联合组患者的治疗总有效率为47.22%,高于常规组患者的23.33%,差异有统计学意义(P﹤0.05)。治疗后,两组患者CYFRA21-1、CEA、NSE水平均低于本组治疗前,联合组患者CYFRA21-1、CEA、NSE水平均低于常规组,差异均有统计学意义(P﹤0.05)。治疗后,两组患者IFN-γ、IL-2、TNF-α水平均高于本组治疗前,IL-6、IL-10水平均低于本组治疗前,联合组患者IFN-γ、IL-2、TNF-α水平均高于常规组,IL-6、IL-10水平均低于常规组,差异均有统计学意义(P﹤0.05)。治疗期间,联合组患者的不良反应总发生率为5.56%,低于常规组患者的23.33%,差异有统计学意义(P﹤0.05)。结论特瑞普利单抗联合一线化疗治疗晚期NSCLC患者的疗效显著,可改善细胞因子和肿瘤标志物水平,且安全性较高。Objective To investigate the application effect of toripalimab combined with first-line chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).Method According to different treatment plans,66 NSCLC patients were divided into conventional group(n=30)and combination group(n=36).Patients in the conventional group received conventional chemotherapy,while patients in the combination group received conventional chemotherapy combined with toripalimab treatment.The clinical efficacy,tumor markers[cyto-keratin 19 fragment antigen 21-1(CYFRA21-1),neuron specific enolase(NSE),carcinoembryonic antigen(CEA)]levels,cytokine[interferon-γ(IFN-γ),interleukin(IL)-2,tumor necrosis factor-α(TNF-α),IL-6,IL-10]levels,and incidence of adverse reactions were compared between the two groups.Result The total effective rate in combination group was 47.22%,which was higher than 23.33% in conventional group,and the difference was statistically significant(P<0.05).After treatment,the levels of CYFRA21-1,CEA,and NSE in both groups were lower than those before treatment,the levels of CYFRA21-1,CEA,and NSE in combination group were lower than those in conventional group,and the differences were statistically significant(P<0.05).After treatment,the levels of IFN-γ,IL-2,and TNF-α in both groups were higher than those before treatment,while the levels of IL-6 and IL-10 were lower than those before treatment,the levels of IFN-γ,IL-2,and TNF-α in the combination group were higher than those in the conventional group,while the levels of IL-6 and IL-10 were lower than those in the conventional group,and the differences were statistically significant(P<0.05).During the treatment period,the total incidence of adverse reactions in combination group was 5.56%,which was lower than 23.33% in conventional group,and the difference was statistically significant(P<0.05).Conclusion Toripalimab combined with first-line chemotherapy has significant efficacy in the treatment of advanced NSCLC patients,which can improve cytokine and tumor ma

关 键 词：特瑞普利单抗 一线化疗 晚期非小细胞肺癌 细胞因子 

分 类 号：R734.2[医药卫生—肿瘤]